Torrent Pharma gets USFDA EIR for Indrad facility
Ahmedabad: Torrent Pharma has informed in a BSE filing that the U.S. Food and Drug Administration (USFDA) has issued Establishment Inspection Report (“EIR”) with Voluntary Action Indicated (“VAI”) classification for the manufacturing facility at Indrad, Gujarat. The inspection has now been successfully closed by the USFDA.
VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action
The USFDA had conducted inspection at the facility from 03-Jun-24 to 12-Jun-24 and issued five observations.
Read also: Torrent Pharma gets 5 USFDA observations for Indrad facility
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).
Read also: Torrent Pharma is said to seek raising USD 3 billion for KKR stake in JB Chemicals: Report
